

# **NEOSE TECHNOLOGIES PRESENTS POSITIVE PHASE I NE-180 CLINICAL TRIAL DATA**

Neose Technologies

*Drug Week, January 05, 2007*

Neose Technologies, Inc. (GM:NTEC) presented positive data from its NE-180 Phase I clinical trial during the American Society of Hematology 48th Annual Meeting and Exposition.

The data were presented in a poster entitled, "NE-180, a Novel GlycoPEGylated Erythropoietin, Demonstrates Dose-Dependent Activity in a Phase 1, Single Dose, Dose Escalation Study in Normal Human Volunteers."

NE-180 is being developed for the treatment of anemia associated with chronic kidney disease, including patients on dialysis and patients not on dialysis, and for the treatment of anemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

Single doses of NE-180, up to 1.5mcg/kg, were generally well tolerated with no serious adverse events. Single doses of NE-180 demonstrated potent, dose-dependent erythropoietic activity. The results from the Phase I study support a Phase II program in patients with anemia associated with chronic kidney disease, dosed every four weeks, and in cancer patients receiving chemotherapy, dosed every three weeks.

Neose Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation therapeutic proteins that are competitive with best-in-class protein drugs currently on the market.